SNDX

+ Watchlist + Portfolio

Syndax Pharmaceuticals, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $20.77
52-Week Range: $12.99 – $25.59
Market Cap: $1.76B
P/E (TTM): —
EPS (TTM): -2.51
Dividend Yield: —

Advanced Metrics

Price/Book: 116.86
PEG Ratio: —
Return on Equity: -255.93%
Return on Assets: -18.67%
Gross Margin: -8.01%
Operating Margin: -54.95%
Profit Margin: -87.52%
Current Ratio: 6.77
Debt/Equity: 39.03
Total Debt: $589.38M
Free Cash Flow: $-150.08M
Revenue Growth: 91.80%
Earnings Growth: —
Enterprise Value: $1.80B

SNDX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$23.68M	$172.35M
Cost of Revenue	$0.00	$0.00	$826.00K	$6.97M
Gross Profit	$0.00	$0.00	$22.85M	$165.38M
Research & Development	$118.50M	$163.03M	$241.65M	$258.78M
Selling, General & Admin	$33.26M	$66.92M	$120.88M	$179.68M
Operating Expenses	$151.76M	$229.95M	$362.53M	$438.47M
Operating Income	-$151.76M	-$229.95M	-$339.67M	-$273.08M
EBITDA	-$146.17M	-$209.14M	-$313.82M	-$251.63M
Pretax Income	-$149.34M	-$209.36M	-$318.76M	-$285.42M
Net Income	-$149.34M	-$209.36M	-$318.76M	-$285.42M
Diluted EPS	-2.46	-2.98	-3.72	-3.29
Diluted Shares	60.76M	70.37M	85.62M	86.63M

SNDX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$74.36M	$295.39M	$154.08M	$134.93M
Receivables	$4.06M	$1.23M	$13.87M	$70.29M
Inventory	—	$0.00	$366.00K	$32.75M
Current Assets	$489.79M	$580.88M	$603.06M	$528.08M
Total Assets	$497.24M	$612.88M	$724.82M	$529.71M
Current Liabilities	$29.07M	$58.10M	$103.55M	$120.12M
Long-Term Debt	—	—	$331.56M	$343.91M
Total Debt	$1.16M	$1.64M	$345.74M	$345.43M
Total Liabilities	$29.79M	$58.68M	$436.69M	$465.08M
Retained Earnings	-$693.04M	-$902.40M	-$1.22B	-$1.51B
Shareholders' Equity	$467.45M	$554.20M	$288.12M	$64.63M
Working Capital	$460.72M	$522.78M	$499.51M	$407.96M
Net Debt	—	—	$189.60M	$208.98M

SNDX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$133.68M	-$160.60M	-$274.90M	-$322.98M
Capital Expenditure	—	—	—	-$187.00K
Free Cash Flow	-$133.68M	-$160.60M	-$274.90M	-$323.17M
Depreciation & Amortisation	$33.00K	$12.00K	$8.00K	$6.00K
Stock-Based Compensation	$16.02M	$30.95M	$43.03M	$47.50M
Investing Cash Flow	-$186.19M	$117.61M	-$219.78M	$290.04M
Financing Cash Flow	$172.25M	$264.13M	$353.37M	$13.68M
Net Change in Cash	-$147.61M	$221.14M	-$141.31M	-$19.27M

SNDX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$20.04M	$37.96M	$45.87M	$68.73M	$64.86M
Cost of Revenue	$885.00K	$1.28M	$2.10M	$2.71M	$2.63M
Gross Profit	$19.16M	$36.68M	$43.77M	$66.02M	$62.23M
Research & Development	$61.64M	$62.23M	$56.28M	$78.64M	$58.84M
Selling, General & Admin	$41.03M	$43.80M	$44.92M	$49.93M	$37.59M
Operating Expenses	$102.91M	$106.03M	$101.20M	$128.57M	$96.43M
Operating Income	-$83.76M	-$69.35M	-$57.43M	-$62.55M	-$34.20M
EBITDA	-$76.80M	-$63.99M	-$52.43M	-$58.42M	-$30.82M
Pretax Income	-$84.85M	-$71.85M	-$60.72M	-$68.01M	-$42.67M
Net Income	-$84.85M	-$71.85M	-$60.72M	-$68.01M	-$42.67M
Diluted EPS	-0.98	-0.83	-0.70	-0.78	-0.48
Diluted Shares	86.17M	86.34M	86.62M	87.36M	88.26M

SNDX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$153.99M	$108.64M	$116.81M	$134.93M	$130.89M
Receivables	$21.48M	$37.42M	$43.06M	$70.29M	$60.69M
Inventory	$4.66M	$17.70M	$25.00M	$32.75M	$34.95M
Current Assets	$548.75M	$531.68M	$529.83M	$528.08M	$471.18M
Total Assets	$640.71M	$596.15M	$551.79M	$529.71M	$472.67M
Current Liabilities	$94.55M	$112.99M	$114.19M	$120.12M	$86.17M
Long-Term Debt	—	—	—	$343.91M	$343.96M
Total Debt	$1.84M	$1.68M	$1.52M	$345.43M	$345.36M
Total Liabilities	$425.65M	$438.73M	$436.36M	$465.08M	$431.05M
Retained Earnings	-$1.31B	-$1.38B	-$1.44B	-$1.51B	-$1.55B
Shareholders' Equity	$215.06M	$157.42M	$115.43M	$64.63M	$41.62M
Working Capital	$454.20M	$418.69M	$415.64M	$407.96M	$385.00M
Net Debt	—	—	—	$208.98M	$213.07M

SNDX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$95.16M	-$87.80M	-$70.53M	-$69.49M	-$50.34M
Capital Expenditure	—	—	—	-$56.00K	—
Free Cash Flow	-$95.16M	-$87.80M	-$70.67M	-$69.54M	-$50.34M
Depreciation & Amortisation	$0.00	$0.00	$3.00K	$3.00K	$4.00K
Stock-Based Compensation	$10.38M	$13.79M	$12.08M	$11.25M	$12.05M
Investing Cash Flow	$94.14M	$41.89M	$72.43M	$81.58M	$38.39M
Financing Cash Flow	$930.00K	$551.00K	$6.28M	$5.92M	$7.92M
Net Change in Cash	-$90.00K	-$45.36M	$8.17M	$18.01M	-$4.04M

Market Snapshot

About

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies for cancer patients. The company focuses on entinostat, an oral HDAC inhibitor, and other epigenetic modulators in combination with immunotherapies and targeted agents. Syndax is advancing multiple clinical programs targeting both hematologic malignancies and solid tumors.